CD38 and Miyoshi myopathy: A rational strategy by affinity optimization has been established to diminish the undesired on-target off-tumor effects, and T cells expressing CD38-directed CARA4, which had reduced affinity (KD 10−7 M to 10−5 M), could selectively eliminate CD38++ MM cells, but spare CD38+ HPCs and T cells [40].